Lundbeck is a global pharmaceutical company specializing in brain disease.
Denmark-based Lundbeck (LUN: CO) is a global pharmaceutical company specializing in brain disease and the central nervous system. It is headquartered in Copenhagen, and has international production facilities in Mexico, Italy and France. It employs around 6,000 people worldwide.
Lundbeck markets a number of different pharmaceuticals for the treatment of brain diseases. The most recently launched compounds include: Brintellix (depression), Cipralex/Lexapro (depression), Abilify Maintena (schizophrenia), Selincro (alcohol dependence), Azilect (Parkinson’s disease), Xenazine (chorea associated with Huntington's disease), Sabril (epilepsy) and Onfi (Lennox-Gastaut syndrome). Its key products are the serotonin modulator and stimulator Brintellix, selective serotonin reuptake inhibitor Lexapro and antidementia agent Ebixa.
Each year, Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain diseases.
In 2013, 46% of its revenue derived from Europe, 17% from the USA and 27% from the International Markets region.